Estrogens play a crucial role in the development of breast cancer. Estradiol can be produced in the breast tissue in situ, and one of the enzymes involved in this process is 17b-hydroxysteriod dehydrogenase (17b-HSD) type 1 that catalyzes the interconversion of estrone (E1) to the biologically more potent estradiol (E2). The gene coding for 17b-HSD type 1 (HSD17B1) is located at 17q12-21, close to the more studied ERBB2 and BRCA1. The aim of this study was to investigate if HSD17B1 shows an altered gene copy number in breast cancer. We used real-time PCR and examined 221 postmenopausal breast tumors for amplification of HSD17B1 and ERBB2. In all, 32 tumors (14.5%) showed amplification of HSD17B1 and 21% were amplified for ERBB2. Amplification of the two genes was correlated (P ¼ 0.00078) and in 14 tumors (44%) with amplification of HSD17B1, ERBB2 was co amplified. The patients with amplification in at least one of the genes had a significantly worse outcome than patients without (P ¼ 0.0059). For estrogen receptor (ER)-positive patients who received adjuvant tamoxifen, amplification of HSD17B1 was related to decreased breast cancer survival (P ¼ 0.017), whereas amplification of ERRB2 was not. Amplification of HSD17B1 might be an indicator of adverse prognosis among ER-positive patients, and possibly a mechanism for decreased benefit from tamoxifen treatment.
Introduction
Breast cancer is one of the most common malignancies in women worldwide and is also a major cause of cancer-related deaths among women. Estrogens play an important role in the development of hormone-dependent breast cancer. In postmenopausal women estrogens in breast carcinoma tissue originate through two main pathways, one involving aromatase, which converts androgens to estrogens, and the other utilizing sulfatase, which converts estrone sulfate into estrone. Previous studies have suggested that estradiol can be produced in the same organ where it exerts its biological response. This is also in agreement with the fact that breast cancer tissue possesses all the enzymes necessary for the bioformation of estradiol (Yue et al., 1998; Purohit et al., 2002) . Among these enzymes are 17b-hydroxysteriod dehydrogenases (17b-HSD), which control the final step in the formation of androgens and estrogens (Labrie et al., 1997) . The 17b-HSD type 1 enzyme uses NADPH as a cofactor and catalyzes the interconversion of the weak estrogen, estrone (E1), to the biologically more potent estradiol (E2). 17b-HSD type 2 uses NAD+ as a cofactor and catalyzes the oxidation of testosterone and estradiol to form androstendione and estrone, respectively (Miettinen et al., 1996; Vihko et al., 2001) .
A recent study showed that the ratio of bioactive estradiol to estrone (E2/E1) in breast tumors as well as the expression level of 17b-HSD type 1 mRNA was higher among postmenopausal than premenopausal patients (Miyoshi et al., 2001) . A few immunohistochemical studies of 17b-HSD type 1 in human breast cancer have been reported, and these suggest that 17b-HSD 1 may play an important role in the in situ regulation of estradiol production in hormone-dependent breast carcinomas (Poutanen et al., 1992; Sasano et al., 1996; Suzuki et al., 2000) . In a previous study, we found that the expression of both 17b-HSD types 1 and 2 differs in breast cancers with or without late relapse in the disease. Patients with late relapse more often had a high expression of 17b-HSD type 1 or loss of 17b-HSD type 2 (Gunnarsson et al., 2001) .
The gene encoding 17b-HSD type 1 (HSD 17B1) is located at 17q12-21, a region that often is rearranged in breast cancer (Plummer et al., 1997; Kauraniemi et al., 2001) . This region also harbors ERBB2, which is described as the most amplified gene in breast cancer. In 20-30% of all breast cancers ERBB2 is overexpressed. High expression is common in ER-negative tumors and gives rise to a worse prognosis (for reviews see Re`villion et al., 1998) . In a majority of breast carcinomas with ERBB2 amplification the neighboring topoisomerase IIa gene is either amplified or deleted, which in turn has importance for the response to chemotherapy (Ja¨rvinen et al., 2000) . Furthermore, frequent loss of heterozygosity has been observed at several loci on 17q, and the tumor suppressor gene BRCA1 is located at 17q21 (Bie`che and Lidereau, 1995; Osborne and Hamshere, 2000) .
The aim of this study was to investigate if the gene encoding 17b-HSD type 1 exhibits altered gene copy number in breast cancer. Using real-time PCR and the TaqMan methodology, we examined 221 tumors from postmenopausal patients for gene amplification of HSD17B1 and ERBB2. As a control, we examined the mRNA expression of 17b-HSD type 1 in a subgroup of tumors.
Results
Using the amyloid precursor protein (APP) gene as a reference, the HSD17B1 to APP and ERBB2 to APP copy-number ratios were calculated in 221 tumors. Samples with values higher than 2 were considered amplified, whereas samples with levels lower than 0.5 were considered to have a decreased copy number. The mean normalized HSD17B1 level was 1.32 (range 0.2-7.9). In all, 32 tumors (14.5%) showed a value higher than 2 and an equal number of tumors showed a value lower than 0.5. The remaining 71% of the tumors had values clustered around the normal level (mean 1.14, 95% CI 1.08-1.21). Figure 1 illustrates a case with and without amplification, respectively. For ERBB2, the mean value was 2.03 (range 0.3-25.4), with 21% of the tumors showing gene amplification, 14% showing a low copy number and 65% showing normal gene levels (mean 0.96, 95% CI 0.90-1.02). In total, 83% of the tumors with amplification of ERBB2 had a high protein expression compared with 13% of those without gene amplification (Po0.00001). Only two out of 32 tumors with a low copy number showed overexpression of the protein. A total of 14 out of the 32 tumors (44%) with HSD17B1 amplification showed at the same time amplification of ERBB2, and the correlation between HSD17B1 and ERBB2 amplification was statistically Figure 1 HSD17B1 and APP gene quantity by real-time PCR in two breast tumor samples. The threshold cycle (C t ) values for APP were almost identical in the two samples, whereas a shift in C t was evident for HSD17B1, indicating different gene-copy ratios in the two samples, the actual gene-copy ratios were calculated from the standard curves obtained in the same experiment (not shown). The measurements were made in triplicates for each sample Amplification of HSD17B1 in breast cancer C Gunnarsson et al significant (P ¼ 0.00078, Table 1 ). No correlation was observed between decreased copy number of HSD17B1 and altered ERBB2.
No association was found between HSD17B1 amplification and lymph node status (P ¼ 0.71), tumor size (P ¼ 0.80) or estrogen receptor (ER) status (P ¼ 0.88). Patients with ERBB2 amplification were to a higher degree ER negative (P ¼ 0.0028), and had larger tumors compared to others (P ¼ 0.016). A total of 48 tumors were examined with regard to the mRNA expression of 17b-HSD type 1, among which 16 tumors showed HSD17B1 amplification, 15 tumors had normal gene copy number and 17 tumors showed a low copy number. The median (range) expression level in the groups with low, normal and increased gene copy number was 0.8 (0.4-1.9), 1.5 (0.7-14.6), and 2.1 (0.9-8.6), respectively. The difference was statistically significant (P ¼ 0.0010, Kruskal-Wallis test). Dividing the tumors by expression level into three categories also showed a significant association between gene copy number and expression level (Table 2) .
Patients with amplification of either HSD17B1 or ERBB2 or both showed lower breast cancer survival than patients without amplification (P ¼ 0.0059). Both amplifications appeared to indicate worse outcome independently ( Figure 2a ). HSD17B1 turned out to be an independent prognostic factor with borderline significance (P ¼ 0.052) in multivariate analysis adjusting for lymph node status, tumor size, ER status, ERBB2 amplification and treatment (Table 3 ). The prognostic importance of HSD17B1 amplification was greatest for the ER-positive patients who had received tamoxifen (P ¼ 0.017, Figure 2b ), while there was no significant difference for ERBB2 in the same group of patients (P ¼ 0.98). In the ER-negative subgroup patients with ERBB2 amplification had worse prognosis compared to those without amplification (P ¼ 0.046, Figure 2c ).
Discussion
Estradiol plays a crucial role in breast cancer evolution and it has been shown that in normal breast tissue the oxidative pathway (E2-E1) dominates, whereas in malignant breast tumors the reductive pathway (E1-E2) is dominant (Speirs et al., 1998a, b) . 17b-HSD type 1 is the principal enzyme responsible for the conversion of estrone (E1) to the more biologically active estradiol (E2) (Luu-Thee et al., 1995) . These results suggest that intratumoral regulation of estradiol levels is possible. Miyoshi et al. (2001) observed that mRNA levels of 17b-HSD type 1, more evident than aromatase and sulfatase levels, were higher in postmenopausal than premenopausual tumors, and they suggested that upregulation of 17b-HSD type 1 is important in the maintenance of high intratumoral E2 levels in postmenopausal patients. On the other hand, Utsumi et al. (1999) suggested steroid sulfatase as a useful prognostic marker for the identification of high-risk breast cancer patients. Feigelson et al. (2001) found that a polymorphism in the gene coding for 17b-HSD type 1 might be used to identify women with an increased risk for advanced breast cancer. In the present study, we found amplification of this gene in 14.5% of the cases, and provided that this leads to overexpression of the enzyme, it might be a mechanism of a high E1 to E2 conversion rate in the tumor.
The gene encoding 17b-HSD type 1 is located at 17q12-21 and this region shows frequent genetic rearrangement (Plummer et al., 1997) . The HSD17B1 gene originally was a candidate gene for BRCA1 (Mannermaa et al., 1994) . After it was eliminated as a candidate, it has received little attention despite its putative importance in the synthesis of estradiol. Several other genes that have been related to breast cancer are located within the same chromosomal bands. Among those, both ERBB2 and the gene encoding topoisomerase IIa exhibit gene amplification, and recently new amplified and highly expressed genes were discovered in the 17q12 region (Kauraniemi et al., 2001) . We found ERBB2 amplification in 21% of the cases, which falls in the range known from previous studies. We also observed a decreased copy number in 14% of ERBB2. Similarly, a low copy number of HSD17B1 was seen in 15% of the tumors, and this correlated with a low expression of mRNA. In the 17q11-21 region not only amplifications but also deletions have been described (Osborne and Hamshere, 2000) . Among the tumors with gene amplification of HSD17B1, 44% showed coamplification of ERBB2. Coamplification with ERBB2 has earlier been shown in the genes coding for topoisomerase IIa (Ja¨rvinen et al., 2000) , MLN 64 (Bie`che et al., 1996) and placental lactogen, but in the latter case the clinical relevance can be discussed (Latham et al., 2001 ). The position of HSD17B1 appears not to be close to the center of the ERBB2 amplicon and the gene might belong to a neighboring amplicon within 17q12-21. We have estimated the distance between the two genes to be 2.9 Mb (NCBI Map Viewer). The gain in gene copy number was moderate in most of the amplified tumors as was the overexpression of the gene. On the other hand, the clinical outcome was significantly worse among patients with HSD17B1 amplification, which was further supported by the multivariate analysis (Table 3 ). In particular, ER-positive patients who received tamoxifen, a group with good prognosis in general, showed decreased breast cancer survival if the tumor showed amplification of HSD17B1 (P ¼ 0.017). Still, the observed correlation between HSD17B1 amplification and poor prognosis might just be a marker for another nearby gene. In a previous immunohistochemical study no correlation was found between 17b-HSD type 1 and prognosis (Suzuki et al., 2000) . However, this study consisted of a relatively small number of patients and no adjustment was made for ER status. We have previously found that high mRNA expression of 17b-HSD type 1 or low mRNA expression of 17b-HSD type 2 predicts recurrence among ERpositive patients (Gunnarsson et al., 2001 ). Some ER-positive patients with metastatic disease who have failed on tamoxifen still respond to aromatase inhibitors (Dowsett, 1997) . In the presence of high intratumoral estradiol levels, tamoxifen may not fully block the action of estrogen. This could point out amplification of HSD17B1 as a possible event in tamoxifen resistance, and future studies may show whether it could be a marker for treatment with selective estrogen metabolism modulators such as aromatase inhibitors. Interestingly, Ellis et al. (2001) found that the relative benefit from levastrol as compared to tamoxifen was significantly higher among ErbB2-positive patients. Whether ErbB2 is an independent indicator of tamoxifen resistance is still a question of debate. The present study did not demonstrate an interaction between ERBB2 amplification and benefit from tamoxifen. However, this could be because of the statistical power since the ER+/ ERBB2+ subgroup comprised few patients.
Among the tumors without HSD17B1 amplification, some still show a high mRNA expression. Gene amplification is probably not the only reason for overexpression of type 1 and a lot of knowledge about the regulation of 17b-HSD type 1 is still missing. Speirs et al. (1998a Speirs et al. ( , 1999 suggested that cytokines can regulate the E2 synthesis in breast cancer by stimulating enzyme activity, they especially pointed out IL-6 and IL-8 as possible estrogen modulators. Other studies have also shown that IL-6 can upregulate HSD17B1 (Purohit et al., 2002) .
As far as we know, this is the first study reporting on amplification of the gene coding for 17b-HSD type 1. This event may lead to higher levels of estradiol in the tumor. We found that amplification of the gene had prognostic significance. In particular, an increased gene copy number indicated a decreased breast cancer survival for ER-positive patients who received tamoxifen treatment.
Materials and methods

Patients and tumors
The postmenopausal patients in this study were randomized to adjuvant chemotherapy or postoperative radiotherapy. The patients had either histologically verified lymph node metastases or a tumor diameter exceeding 30 mm. The patients did not receive any preoperative treatment. Surgery consisted of modified radical mastectomy. For most of the patients randomized to chemotherapy, the treatment consisted of 12 courses of CMF given according to the original Milan protocol (cyclophosphamide 100 mg/m 2 orally on days 1-14, metotrexate 40 mg/m 2 i.v. on days 1 and 8, and 5-fluorouracil 600 mg/m 2 i.v. on days 1 and 8). Radiotherapy was given with the high-voltage technique with a total dose of 46 Gy. Using a 2 Â 2 factorial study design, the patients were also randomized between tamoxifen or no adjuvant endocrine therapy. Tamoxifen treatment was given postoperatively at a dose of 40 mg daily for at least 2 years. The current study included a subset consisting of 221 patients from whom frozen tumor tissue was still available after hormone receptor assays. This number did not include samples that showed a low percentage of malignant cells (o50%) as judged from a 5 mm tissue section adjacent to the 25 mm section used for DNA extraction. The patients were followed for a median period of 11.3 years, and deaths due to breast cancer were registered in 102 cases during the follow-up period. ER content was measured with immunoassays (Abbott Laboratories, Chicago, IL, USA). Samples with >0.1 fmol/mg DNA were classified as positive.
Protein expression
Overexpression of the ErbB2 protein was quantified with an immunocytochemical method using flow cytometry (Sta˚l et al., 1994) . Briefly, a cell suspension was prepared from frozen tissue and fixed in 1% PFA for 3 min. The cells were incubated Amplification of HSD17B1 in breast cancer C Gunnarsson et al with a monoclonal antibody (c-neu, Ab-2, Oncogene Research Products, Cambridge, MA, USA), or an irrelevant isotype control antibody, followed by incubation with a secondary FITC-conjugated antibody. A measure of erbB2 expression was calculated from the paired samples. The cut off value for overexpression was the same as used in previous studies (Sta˚l et al., 2000) .
DNA extraction
Tumor tissue was disintegrated with scissors and then digested with 50 ml proteinase K (10 mg/ml, Boehringer Mannheim) in 500 ml TEN buffer (10 mm Tris, 1 mm EDTA, 100 mm NaC1) containing 100 ml SDS (20%) and incubated at 551C. DNA was separated from proteins by repeated extractions with phenol, phenol/chloroform (1 : 1) and chloroform. Nucleic acids were precipitated by addition of two volumes of ice-cold 95% ethanol and 1/10 volume 3 m sodium acetate incubated overnight at À201C. DNA was pelleted by centrifugation at 15 000 Â g for 1 h, after which salt residues and RNA were removed by washing with 70% ethanol. Nucleic acids were repelleted as above for 10 min and then vacuum-dried and suspended in sterile Milli-Q water.
RNA extraction
Frozen breast tumor tissue (30 mg), was homogenized in a microdismembrator (B. Brown, Melsungen, Germany) and the total RNA was extracted using the SV Total RNA Isolation System (Promega, SDS, Sweden). The purified RNA was stored at À701C and the concentration of RNA content was determined by spectrophotometry.
cDNA synthesis
In all, 400 ng of total RNA was reverse transcribed in a final volume of 20 ml using the GIBCO BRL kit (Invitrogen, Sweden) with the following concentrations: 1 Â first strand buffer, 0.5 mm dNTP, 2.5 mm random hexamers, 10 mm DTT, 0.5 ml Superscript II reverse transcriptase (Invitrogen, Sweden). The thermal conditions used were: 201C for 10 min, 421C for 50 min, 991C for 5 min, and 51C for 5 min. The samples were stored at 41C until analyzed.
Primers and probes
Primers and probes were designed to recognize human HSD17B1, ERBB2 and APP (amyloid precursor protein), which was used as reference gene. The location of this gene at 21q21 is not known to show chromosomal alterations in breast cancer (Bie`che et al., 1998; Osborne and Hamshere, 2000) . The primer and probe sequences used were as follows: HSD17B1:
0 (probe); and APP:
0 -CCCTGAACTGCAGATCAC-CAATGTGGTAG-3 0 (probe). Both primers and probes were purchased from Applied Biosystems.
Primers and probe were designed to recognize human 17b-HSD type 1 cDNA sequences using the computer program Primer Express (Applied Biosystems) and b-actin was used as endrogenous control (Applied Biosystems). The primer and probe sequences for 17b-HSD type 1 were as follows:
0 (probe). We conducted Blast searches (Genbank) to confirm the specificity of nucleotide sequences chosen for the primers and probes and the absence of DNA polymorphism. To avoid detection of contaminating genomic DNA, the probe was placed at the junction between two exons.
Real-time polymerase chain reaction
All reactions were performed in the ABI Prism 7700 Sequence Detection System (Applied Biosystems) using TaqMan methodology. Reactions are characterized by the point during cycling when amplification of the PCR product is first detected, rather than the amount of PCR product after a fixed number of cycles. The design of the TaqMan probes, combined with the 5 0 -3 0 nuclease activity of AmpliTaq Gold DNA polymerase (Applied Biosystems), allows the direct detection of the PCR product by the release of a fluorescent reporter during the PCR. We examined the DNA content of HSD17B1 and ERBB2 using APP as a control gene in the 221 tumors. The breast cancer cell line MDA-MB-231 was used to construct standard curves. MDA-MB-231 was purchased from American type culture collection (ATCC). MDA-MB-231 cells show normal gene copy levels at 21q21 and 17q12-21 (http://www.nhgri.nih.gov/DIR/CGB/CR2000/). We also investigated the mRNA level of 17b-HSD type 1 in 48 of the tumors, using the expression of 17b-HSD type 1 in normal mammary gland as a reference. Total RNA from mammary gland was purchased from Clontech (Becton Dickinson, Sweden).
PCR conditions
cDNA (3 ml) or DNA was added to the reaction mixture that had a total volume of 25 ml. Using TaqMan PCR core Reagent kit (Applied Biosystems), the concentrations used were: 1x TaqMan buffer A, 5.0 mm MgCl, 0.1 mm dNTP, 0.1 mm each of forward and reverse primer, 0.1 mm probe and 0.025 U/ ml AmpliTaq Gold DNA polymerase. The thermal conditions used were 951C for 10 min, 951C for 15 s and 601C for 1 min. Steps two and three were repeated for 50 cycles. The different targets were amplified independently in separate reaction wells, in triplicates. On the same plate we included samples for standard curves for the target genes.
Standard-curve method
A relative kinetic method was applied using a standard curve. This was constructed with four fold serial dilutions of DNA from the breast cancer cell line MDA-MB-231 or of cDNA from normal human breast tissue. The target content in unknown samples was quantified by using the standard curves to determine a relative measure of the starting amount. Each sample was then normalized on the basis of its APP content (DNA) of b-actin content (cDNA).
Statistical analysis
The relationships between grouped variables were analyzed with the w 2 test, or the w 2 test for the trend when required. Survival curves were produced according to the life-table method described by Kaplan and Meier. Differences in breast cancer mortality rates were estimated with Gehan's test. Multivariate analysis of mortality rates was performed with Cox proportional hazard regression. All the procedures are comprised in the statistical package STATISTICA 6.0 (StatSoft Scandinavia AB, Sweden). The criterion for statistical significance was Po0.05.
